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Abstract 
Little is known about the impact of blood rheology on the occurrence of retinopathy in sickle cell 
disease (SCD). Fifty-nine adult SCD patients in steady-state condition participated to the study: 
32 with homozygous SCD (sickle cell anemia; SCA) and 27 with sickle cell hemoglobin-C 
disease (SCC). The patients underwent retinal examination and were categorized according to 
the classification of Goldberg: 1) no retinopathy (group 1), 2) non-proliferative or proliferative 
stage I-II retinopathy (group 2) and 3) proliferative stage III-IV-V retinopathy (group 3). 
Hematological and hemorheological (whole blood viscosity, RBC deformability and aggregation 
properties) measurements were performed for each patient. In the whole SCD group (SCA + 
SCC patients) and in SCC patients, the group 3 had higher platelets count than group 2 but the 
difference between group 3 and group 1 did not reach statistical significance. No difference was 
observed for the other parameters between the three groups. SCC patients from the group 3 
exhibited higher whole blood viscosity than SCC patients from the group 1. No significant 
difference was observed between the three groups in SCA patients. This study revealed that 
severe sickle proliferative retinopathy is associated with blood hyperviscosity in SCC patients 
but not in SCA patients. 
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Introduction 
Retinal disease is the most common ocular complication in sickle cell disease (SCD). A decrease 
of microcirculatory flow at the retinal level may cause ischemia resulting in non-proliferative or 
proliferative retinopathy [17]. The National Institute of Health (NIH) recommends that all 
patients with SCD should have regular dilated retinal examinations by an ophthalmologist with 
expertise in retinal diseases [22]. Ocular fundus may reveal microcirculatory changes at the 
retinal level which are characteristics of retinopathy. Retinopathy is most frequent in patients 
with sickle cell-hemoglobin C disease (SCC) than in patients with sickle cell anemia (SCA) [9]. 
The greater whole blood viscosity usually reported in SCC patients in comparison with SCA 
patients has been hypothesized to increase the risk of SCC patients to develop retinopathy [12]. 
Nevertheless, this association has been poorly studied [21]. It seems that high hemoglobin 
concentration and low fetal hemoglobin level could increase the risks of SCA males and females, 
respectively, to develop sickle retinopathy [10, 13]. In SCC females, high mean cell volume and 
low fetal haemoglobin have been reported to be associated with retinopathy [10, 14]. 
Chronic hemorheological alterations have been reported in SCD [1, 3-4, 6-8, 18, 23, 25, 29] with 
the level of alterations being very different between SCA and SCC patients [29] and highly 
variable from one patient to another for a given -genotype [23, 29-30]. Some of these 
hemorheological disorders are involved in the pathophysiology of SCD and the occurrence of 
acute vaso-occlusive accidents [4, 20, 23-24] but few data regarding the involvement of blood 
rheology in the development of sickle retinopathy is available in the literature. Serjeant et al. 
reported a greater whole blood viscosity (determined at high shear rate) in SCA males with 
sickle retinopathy than in SCA males without retinopathy [26]. The other hemorheological 
parameters investigated were not different between the two populations [26]. In SCC, no 
association between blood rheology and sickle retinopathy has been reported [27]. However, the 
techniques available in the eighties to assess blood rheological characteristics were not as 
reproducible and accurate than the ones currently available [5]. Recent progresses in blood 
rheological techniques make the assessment of red blood cell (RBC) rheological properties easier 
that justify to re-analyze the association of SCD retinopathy with hemorheology. 
We studied the blood rheological profile of 59 patients with SCD and compared each parameter 
between patients with either no retinopathy (group 1), non-proliferative or proliferative stage I-II 
retinopathy (group 2) or proliferative stage III-IV-V retinopathy (group 3).   
 
Materials and Methods 
 
Patients and protocol 
Fifty-nine adult patients with SCD (32 SCA and 27 SCC) and followed annually by the Sickle 
Cell Unit of the Academic Hospital of Pointe à Pitre (Guadeloupe) were included between 
October 2010 and May 2011. All patients were in clinical steady state at the time of the study 
(i.e. without vaso-occlusive crisis, acute medical complication or blood transfusion/phlebotomies 
within the last 3 months). Any treatment potentially modifying the hemorheological 
characteristics of blood and any condition causing a peripheral proliferative retinopathy were 
exclusion criteria. Two independent ophthalmologists performed indirect ophthalmoscopy with a 
non-contact slip lamp lens (SuperField, Volk Optical, Mentor, OH, USA) and patients were 
classified into three groups as proposed by Goldberg et al. [11]: no retinopathy (group 1), non 
proliferative or proliferative stage I-II retinopathy (group 2) and proliferative stage III-IV-V 
retinopathy (group 3). This classification is more accurate than in previous studies which 
investigated associations between blood rheology and sickle retinopathy [10, 26-27]. These 
previous works compared patients with no retinopathy to patients with retinopathy without 
taking into account the increasing severity of retinal ischemic and proliferative lesions. Blood 
was sampled in EDTA tubes for hematological and hemorheological measurements. This study 
received the ethic approval by the Regional Ethics Committee (CPP Sud-Ouest Outre-Mer III, 
Bordeaux, France). The experiments were performed in accordance with the guidelines set by the 
Declaration of Helsinki. 
 
Hematological and hemorheological measurements 
Hemorheological measurements were performed within 4 hours after blood sampling and were 
conducted in accordance with the recent international guidelines for hemorheological laboratory 
techniques after full re-oxygenation of blood for 10-15 min [5].  
Whole blood viscosity (b) was measured using a cone-plate viscometer (Brookfield DVII+ with 
CPE40 spindle) at 25°C and at 90 s
-1
. RBC deformability was determined at 7 increasing shear 
stresses (0.95, 1.69, 3.00, 5.33, 9.49, 16.87 and 30.00 Pa) by laser diffraction analysis 
(Ektacytometry, LORCA, RR Mechatronics, Hoorn, The Netherlands) and at 37°C. The system 
calculates an average RBC elongation index (EI). The higher this index, the more deformable the 
RBCs. RBC aggregation was determined at 37°C via syllectometry (i.e, laser backscatter versus 
time), using the LORCA (RR Mechtronics, Hoom, The Netherlands), after adjustment of 
hematocrit to 40%. The system calculates an RBC aggregation index (AI). The RBC 
disaggregation threshold (thr) – i.e. the minimal shear rate needed to prevent RBC aggregation 
or to break down existing RBC aggregates – was determined using a re-iteration procedure. 
Hematocrit (Hct) was measured after blood microcentrifugation (JOUAN-HEMA-C, Saint 
Herblain, France). Total counts of leukocytes, polynuclear neutrophils, monocytes, lymphocytes, 
eosinophils, platelets and RBCs, percentage of reticulocytes, mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH) and hemoglobin concentration (Hb) were determined 
using a hematology analyzer (Max M-Retic, Coulter, USA).  
 
Statistics 
Hematological and hemorheological parameters were studied in the whole SCD group (SCA + 
SCC patients) and separately in SCA and SCC patients. The hematological and hemorheological 
data were compared between the three groups (group 1 = no retinopathy, group 2 = patients with 
proliferative or non proliferative stages I, II retinopathy and group 3 = patients with proliferative 
stages III-IV-V retinopathy) using a one-way analysis of variance (ANOVA, with Tukey test for 
post-hoc comparisons). Statistical significance was set at p < 0.05. The results are presented as 
mean ± standard error (SD). Analyses were conducted using Statistica (v. 5.5, Statsoft, Tulsa, 
OK, USA). 
 
Results 
Of the 59 SCD patients included, 17 (28.8 %) showed no retinopathy (8 SCC and 9 SCA). The 
ophthalmic examination of the fundus was normal for 29.6% and 28.1% of the SCC and SCA 
patients, respectively. Twenty-four (40.7 %) SCD patients had a non-proliferative or proliferative 
stages I or II retinopathy: 8 SCC (29.6%) and 16 SCA (50%). Proliferative stages III, IV or V 
retinopathy was found in 18 SCD patients (32.7%) with 11 SCC (40.7%) and 7 SCA (21.9%) 
subjects.  
In the whole SCD group (i.e. SCA + SCC patients, table 1) and SCC patients alone (table 2), 
platelet count was significantly higher (p <0.05) in the group 3 than in the group 2. The 
difference between group 1 and group 3 did not reach statistical significance. The other 
hematological, as well as hemorheological, parameters were not different between the three 
groups in the whole SCD group (table 1). SCC patients from the group 3 had higher whole blood 
viscosity than SCC patients from the group 1, and group 2 had values comprised between those 
of the groups 1 and 3. No hematological and hemorheological difference were found between the 
three groups in SCA patients.  
 
Discussion 
Few previous studies investigated the associations between sickle retinopathy and blood 
rheology [26-27]. However, the hemorheological techniques used at that time were much less 
sensitive than the current ones [5]. In addition, no distinction between the different stages of 
retinopathy was made in these studies [26-27]. The present study took into account some of these 
limitations to re-analyze the association between sickle retinopathy and blood rheology.  
 
Our results clearly indicate that sickle retinopathy, and particularly the most severe form 
(proliferative stages III-IV-V), is more frequent in SCC than in SCA patients, which confirm 
previous study [10]. Regular dilated retinal examinations are clearly needed in SCD patients with 
a special attention devoted to SCC patients.  
Since SCC patients have usually higher whole blood viscosity than SCA patients [19, 29] - that 
is also the case in the present study (tables 2 and 3) - it has been hypothesized that SCC patients 
could be prone to a greater risk for retinopathy than SCA patients [12]. SCC patients are clearly 
at a greater risk than SCA patients to develop the most severe forms of retinopathy. However, 
previous results from Serjeant et al. showed no association between blood rheology and the 
development of proliferative retinopathy in SCC or in SCA patients [26-27]. In contrast, we 
clearly demonstrated that the group 3 of SCC patients had a 22% greater whole blood viscosity 
than group 1. The reasons of these divergences between our results and those from Serjeant et al. 
[26-27] remain unknown but one of the major differences is that the severity of the retinal 
ischemic and proliferative lesions was not take into account in the studies from Serjeant et al. 
[26-27]. The higher whole blood viscosity observed in the group 3 may partly impair retinal 
perfusion and oxygenation, thus participating to the development of proliferative retinopathy in 
SCC patients. 
 
Recently, Tripette et al. reported that SCC and SCA patients are characterized by RBC 
aggregation abnormalities [29]. Whereas RBC aggregation is lower than normal values in SCD 
patients, the strength needed to disperse RBC aggregates (i.e. RBC disaggregation threshold) is 
greater than normal values [29-30]. The pathophysiological role of the increased RBC 
disaggregation threshold in SCD has not been frequently assessed but one may suggest that it 
could impair blood flow in microcirculation where RBC aggregates need to be fully dispersed 
before entering into the capillaries [16, 28]. Recently, Lamarre et al. [19] also reported that SCD 
children at risk for acute chest syndrome (ACS) have higher RBC disaggregation threshold than 
SCD children who never developed ACS since birth. No study has tested the association between 
RBC aggregation and sickle retinopathy. The RBC disaggregation values found in the present 
study are in agreement with those previous published [19, 29-30]. However, we found no 
association with sickle retinopathy suggesting that RBC aggregation properties do not play a role 
in this specific SCD complication. 
 
Fox et al. previously shown that high hemoglobin concentration and low fetal hemoglobin level 
could increase the risks of SCA males and females, respectively, to develop sickle retinopathy 
[10]. In SCC females, high mean cell volume and low fetal hemoglobin have been reported to be 
associated with retinopathy [10]. We did not test these associations in function of gender because 
of our limited sample size for each subgroup and more patients are needed to address this issue. 
However, when both males and females were analyzed together, we found no difference for 
hemoglobin concentration, fetal hemoglobin (data not shown) or mean cell volume between the 
three groups categorized according to the retinopathy severity.  
Platelets count was higher in the most severe SCD and SCC groups in comparison with the 
intermediate retinopathy group. One could suggest that the higher platelet count in the most 
severe patients could participate to the alterations of the retinal microcirculatory blood flow since 
they are able to adhere to the endothelium [15]. However, platelets count was not different 
between SCD or SCC patients with no retinopathy (groups 1) compared to patients with 
proliferative stages III-IV-V retinopathy (groups 3). That suggests that platelet count is probably 
not involved in the development or worsening of retinopathy in SCD. 
 
One of the major limitations of the present study is the lack of fluorescein angiography 
measurement which is much more sensitive than indirect ophtalmoscope to detect and quantify 
retinopathy. However, routine exams are more often performed with indirect ophtalmoscope in 
SCD population. On the whole, our study suggests that blood rheology or hematology alone is 
not a risk factor for the development of retinopathy in SCA patients. In contrast, the most severe 
form of sickle retinopathy in SCC patients is associated with blood hyperviscosity. The retinal 
occlusive complications in SCD are probably related to multi-cellular and molecular factors that 
require further studies. Longitudinal studies are needed to follow the evolution of blood rheology 
and the development or not of sickle retinopathy to conclude definitively on the role, or not, of 
blood rheology in this complication.  
 
This study has been done in respect of the principles of ethical authorship for publication in 
Clinical Hemorheology and Microcirculation [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Hematological and hemorheological parameters in SCD patients (SCA + SCC) categorized 
according to retinopathy severity 
 Group 1 (n=17) Group 2 (n=24) Group 3   (n=18) 
Leukocytes (10⁹/l) 7.55 ± 1.90 9.42 ± 3.10 8.73 ± 2.61 
RBCs (10¹²/l) 3.58 ± 0.88 3.36 ± 1.05 3.56 ± 0.81 
Hb (g/100 ml) 9.74 ± 1.80 9.40 ± 2.08 10.04 ± 1.28 
MCV (fl) 77.95 ± 10.85 79.42 ± 9.07 79.83 ± 10.52 
MCH (pg) 27.92 ± 4.27 28.80 ± 3.44 28.96 ± 3.88 
Platelets count (10⁹/l) 351.88 ± 124.99 299.88 ± 135.26 416.72 ± 149.62 † 
Polynuclear Neutrophils (10⁹/l) 3.67 ± 1.15 5.04 ± 1.90 4.80 ± 2.21 
Eosinophils (10⁹/l) 0.31 ± 0.26 0.28 ± 0.21 0.26 ± 0.15 
Lymphocytes (10⁹/l) 2.67 ± 0.66 2.93 ± 1.21 2.77 ± 1.00 
Monocytes (10⁹/ l) 0.85 ± 0.37 1.11 ± 0.63 0.83 ± 0.37 
Reticulocytes (%) 5.02 ± 2.80 5.80 ± 3.37 5.10 ± 3.57 
Lactate dehydrogenase (UI/l) 359.94 ± 120.47 447.60 ± 147.44 348.47 ± 115.49 
Hct (%) 29.54 ± 4.89 28.53 ± 6.24 28.94 ± 4.52 
ηb at 90s-1(mPa/s  8.31 ± 2.28 7.86 ± 2.01 8.98 ± 2.21 
EI at 0.95 Pa 0.06 ± 0.03 0.06 ± 0.04 0.07 ± 0.03 
EI at 1.69 Pa 0.12 ± 0.03 0.10 ± 0.04 0.12 ± 0.03 
EI at 3 Pa 0.19 ± 0.04 0.16 ± 0.05 0.17 ± 0.04 
EI at 5.33 Pa 0.26 ± 0.05 0.22 ± 0.07 0.23 ± 0.06 
EI at 9.49 Pa 0.33 ± 0.06 0.29 ± 0.08 0.30 ± 0.07 
EI at 16.87 Pa 0.39 ± 0.07 0.34 ± 0.09 0.36 ± 0.08 
EI at 30 Pa 0.43 ± 0.08 0.38 ± 0.10 0.40 ± 0.08 
AI (%) 52.78 ± 10.05 50.88 ± 8.41 49.58 ± 9.24 
thr (s-¹) 242.94 ± 74.69 277.41 ± 117.25 309.62 ± 173.74 
 
Group 1: without sickle cell retinopathy, group 2: non-proliferative and proliferative stage I and II retinopathy, 
group 3: proliferative retinopathy of stage III, IV and V. Mean ± SD. RBCs = red blood cells, Hb = hemoglobin 
concentration, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, Hct = hematocrit, ηb = 
whole blood viscosity, EI = Elongation Index (i.e. RBC deformability), AI = RBC aggregation index, thr = RBC 
disaggregation threshold. 
† 
Different from group 2 (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Hematological and hemorheological parameters in SCC patients categorized according to 
retinopathy severity 
           
           
 Group 1   (n=8) Group 2   (n=8) Group 3 (n=11) 
Leukocytes (10⁹/l) 6.58 ± 1.54 8.49 ± 2.44 7.96 ± 2.26 
RBCs (10¹²/l) 4.20 ± 0.48 4.44 ± 0.81 4.08 ± 0.54 
Hb (g/100 ml) 11.18 ± 1.07 11.38 ± 1.40 10.74 ± 0.91 
MCV (fl) 73.78 ± 4.78 71.00 ± 8.36 72.88 ± 4.81 
MCH (pg) 26.72 ± 1.98 26.08 ± 3.50 26.55 ± 2.12 
Platelets count (10⁹/l) 330.63 ± 141.93 210.50 ± 101.26 424.00 ± 159.95 † 
Polynuclear Neutrophils (10⁹/l) 3.11 ± 0.66 5.17 ± 2.00 4.33 ± 1.71 
Eosinophils (10⁹/l) 0.35 ± 0.35 0.17 ± 0.09 0.24 ± 0.13 
Lymphocytes (10⁹/l) 2.39 ± 0.61 2.25 ± 0.74 2.66 ± 0.86 
Monocytes (10⁹/ l) 0.69 ± 0.37 0.86 ± 0.67 0.66 ± 0.28 
Reticulocytes (%) 2.88 ± 1.03 2.18 ± 0.86 3.14 ± 1.57 
Lactate dehydrogenase (UI/l) 269.38 ± 53.56 371.67 ± 155.22 300.00 ± 68.50 
Hct (%) 33.05 ± 3.25 33.25 ± 4.50 30.65 ± 3.71 
ηb at 90s-1(mPa/s  7.39 ± 1.50 9.08 ± 1.45 9.47 ± 1.80 * 
EI at 0.95 Pa 0.06 ± 0.01 0.07 ± 0.03 0.08 ± 0.02 
EI at 1.69 Pa 0.12 ± 0.01 0.12 ± 0.02 0.12 ± 0.02 
EI at 3 Pa 0.19 ± 0.02 0.17 ± 0.02 0.17 ± 0.03 
EI at 5.33 Pa 0.26 ± 0.03 0.24 ± 0.03 0.23 ± 0.05 
EI at 9.49 Pa 0.34 ± 0.05 0.31 ± 0.04 0.30 ± 0.06 
EI at 16.87 Pa 0.40 ± 0.06 0.37 ± 0.05 0.36 ± 0.07 
EI at 30 Pa 0.45 ± 0.07 0.43 ± 0.05 0.40 ± 0.07 
AI (%) 46.96 ± 9.17 47.38 ± 10.10 46.66 ± 6.50 
thr (s-¹) 225.00 ± 66.82 297.14 ± 116.47 283.85 ± 98.86 
 
Group 1: without sickle cell retinopathy, group 2: non-proliferative and proliferative stage I and II retinopathy, 
group 3: proliferative retinopathy of stage III, IV and V. Mean ± SD. RBCs = red blood cells, Hb = hemoglobin 
concentration, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, Hct = hematocrit, ηb = 
whole blood viscosity, EI = Elongation Index (i.e. RBC deformability), AI = RBC aggregation index, thr = RBC 
disaggregation threshold. * Different from group 1 (p < 0.05), 
† 
different from group 2 (p < 0.05). 
 
 
 
 
 
 
 
 
 
Table 3: Hematological and hemorheological parameters in SCA patients categorized according to 
retinopathy severity 
 
 Group 1 (n=9) Group 2   (n=16) Group 3    (n=7) 
Leukocytes (10⁹/l) 8.41 ± 1.83 9.89 ± 3.36 9.94 ± 2.83 
RBCs (10¹²/l) 3.02 ± 0.78 2.83 ± 0.67 2.75 ± 0.35 
Hb (g/100 ml) 8.46 ± 1.26 8.42 ± 1.61 8.96 ± 0.99 
MCV (fl) 81.66 ± 13.51 83.63 ± 6.08 90.74 ± 6.92 
MCH (pg) 28.99 ± 5.51 30.16 ± 2.55 32.74 ± 2.78 
Platelets count (10⁹/l) 370.78 ± 112.98 344.56 ± 129.92 405.29 ± 143.30 
Polynuclear Neutrophils (10⁹/l) 4.18 ± 1.29 4.97 ± 1.91 5.53 ± 2.82 
Eosinophils (10⁹/l) 0.27 ± 0.15 0.33 ± 0.23 0.30 ± 0.18 
Lymphocytes (10⁹/l) 2.91 ± 0.63 3.27 ± 1.27 2.93 ± 1.24 
Monocytes (10⁹/ l) 0.99 ± 0.33 1.23 ± 0.59 1.11 ± 0.35 
Reticulocytes (%) 6.90 ± 2.47 7.61 ± 2.47 8.70 ± 3.44 
Lactate dehydrogenase (UI/l) 440.44 ± 104.98 480.14 ± 136.76 437.33 ± 136.59 
Hct (%) 26.41 ± 3.92 26.01 ± 5.61 26.50 ± 4.70 
ηb at 90s-1(mPa/s  9.03 ± 2.59 7.21 ± 2.00 8.29 ± 2.69 
EI at 0.95 Pa 0.06 ± 0.03 0.05 ± 0.04 0.05 ± 0.04 
EI at 1.69 Pa 0.12 ± 0.04 0.10 ± 0.05 0.11 ± 0.05 
EI at 3 Pa 0.19 ± 0.05 0.15 ± 0.06 0.17 ± 0.06 
EI at 5.33 Pa 0.26 ± 0.06 0.22 ± 0.08 0.23 ± 0.07 
EI at 9.49 Pa 0.32 ± 0.07 0.28 ± 0.10 0.30 ± 0.09 
EI at 16.87 Pa 0.38 ± 0.08 0.32 ± 0.11 0.36 ± 0.10 
EI at 30 Pa 0.42 ± 0.09 0.36 ± 0.11 0.40 ± 0.11 
AI (%) 57.96 ±  8.03 52.51 ± 7.31 53.75 ± 11.39 
thr (s-¹) 258.89 ± 81.50 268.20 ± 120.51 346.43 ± 251.29 
 
Group 1: without sickle cell retinopathy, group 2: non-proliferative and proliferative stage I and II retinopathy, 
group 3: proliferative retinopathy of stage III, IV and V. Mean ± SD. RBCs = red blood cells, Hb = hemoglobin 
concentration, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, Hct = hematocrit, ηb = 
whole blood viscosity, EI = Elongation Index (i.e. RBC deformability), AI = RBC aggregation index, thr = RBC 
disaggregation threshold. 
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